Tag: Rubius Therapeutics
Rubius Therapeutics reports $196.5M loss in 2021
PROVIDENCE – Rubius Therapeutics Inc. on Friday reported a loss of $196.5 million in 2021, or $2.23 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius Therapeutics ramps up R&D costs, reports $49M loss in Q3
PROVIDENCE – Rubius Therapeutics Inc. reported a $49 million loss in the third quarter, or 55 cents per diluted share, a decline from a...
Rubius Therapeutics logs $50.2M loss in Q2
CAMBRIDGE, Mass. – The clinical-stage biopharmaceutical company Rubius Therapeutics Inc. reported a loss of $50.2 million in the second quarter, or 56 cents per...
Rubius Therapeutics posts $42.3M loss in Q1
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
Rubius Therapeutics reports $167.7M loss in 2020
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius Therapeutics reports $40.9M loss in Q3
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter.
The clinical-stage biopharmaceutical...
Rubius Therapeutics
PBN Best Places to Work 2020
MIDSIZE COMPANIES 5. Rubius Therapeutics
Employees in R.I.: 64
CEO Pablo J. Cagnoni
Questions answered by: Human Resources Site Head Brianne Meehan
What...
PBN announces 2020 Best Places to Work honorees
PROVIDENCE – Providence Business News has announced 66 honorees for its 2020 Best Places to Work program.
Each of the companies recognized for this year’s...
Rubius Therapeutics posts $48.5M loss in Q1; prioritizes on oncology and...
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. posted a loss of $48.5 million for the first quarter of 2020, or a loss of 60 cents...
Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and...
PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018.
Loss per diluted share...
- Featured Event -
